Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Group 1 - Adaptive Biotechnologies (ADPT) has shown a year-to-date return of approximately 15.4%, outperforming the Medical sector average return of -3.8% [4] - The Zacks Consensus Estimate for ADPT's full-year earnings has increased by 8.5% over the past three months, indicating improved analyst sentiment [4] - Adaptive Biotechnologies is part of the Medical - Biomedical and Genetics industry, which has an average loss of 13.6% this year, further highlighting ADPT's strong performance [6] Group 2 - Bio-Rad Laboratories (BIO) has a year-to-date return of 4.9% and has also outperformed the Medical sector [5] - The consensus EPS estimate for Bio-Rad Laboratories has increased by 2.3% over the past three months, reflecting positive analyst outlook [5] - Bio-Rad Laboratories belongs to the Medical - Products industry, which has seen a year-to-date increase of 14.1% [7]